Company intelligence / Profile preview

Eyes on the Future

London, England, United Kingdomeyesonthefuture.org.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

Eyes on the Future is a UK-based non-profit that supports and helps fund the development of gene therapies for inherited retinal diseases, specifically those caused by mutations in the RDH12 gene. Its major collaborative project is currently at the pre-clinical stage, with the goal of supporting an IND filing by late 2025[1][2][4].

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Academic Hospital/University/Research

Partnerships

Opus GeneticsGlobal RDH12 AllianceRDH12 Fund for Sight

Beyond the preview

Go deeper on Eyes on the Future.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyes on the Future.

Explore the full profile